Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 4
Submit an article Journal homepage
151
Views
27
CrossRef citations to date
0
Altmetric
Reviews

Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?

Gregory A Jicha University of Kentucky College of Medicine, Sanders-Brown Center on Aging, Alzheimer's Disease Center, Department of Neurology, 800 South Limestone Street, Lexington, KY 40536-0230, USA +1 859 257 1412, ext 255; +1 859 257 3819; [email protected]
, MD PhD
Pages 481-491 | Published online: 03 Apr 2009

Bibliography

  • Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008;31:175-93
  • Gardberg AS, Dice LT, Ou S, et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci USA 2007;104(40):15659-64
  • Geylis V, Steinitz M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Aβ) human monoclonal antibodies. Autoimmun Rev 2006;5(1):33-9
  • Hawkes CA, McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 2007;7(11):1535-48
  • Hock C, Koietzko U, Streffer JR, et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38(4):547-54
  • Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem 2008;104(4):859-74
  • Mattson MP, Chan SL. Good and bad amyloid antibodies. Science 2003;301(5641):1847-9
  • Morgan D, Gitter BD. Evidence supporting a role for anti-Aβ antibodies in the treatment of Alzheimer's disease. Neurobiol Aging 2004;25(5):605-8
  • Neff F, Wei X, Nölker C, et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008;7(6):501-7
  • Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 2004;140(8):627-38
  • Solomon B. Beta-amyloid-based immunotherapy as a treatment of Alzheimers disease. Drugs Today (Barc) 2007;43(5):333-42
  • Solomon B. Clinical immunologic approaches for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 2007;16(6):819-28
  • Solomon B. Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther 2007;9(1):79-85
  • Foster JK, Verdile G, Bates KA, Martins RN. Immunization in Alzheimer's disease: naive hope or realistic clinical potential? Mol Psychiatry 2008; published online 28 October 2008; doi: 10.1038/mp.2008.115
  • Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. Expert Opin Biol Ther 2008;8(5):633-42
  • Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol 2008;7(9):805-11
  • Dasilva KA, Aubert I, McLaurin J. Vaccine development for Alzheimer's disease. Curr Pharm Des 2006;12(33):4283-93
  • Lemere CA, Maier M, Peng Y, et al. Novel Aβ immunogens: is shorter better? Curr Alzheimer Res 2007;4(4):427-36
  • Maier M, Seabrook TJ, Lemere CA. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. Neurodegener Dis 2005;2(5):267-72
  • Ferrer I, Boada Rovira M, Sánchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol 2004;14(1):11-20
  • Fox NC, Black RS, Gilman S, et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64(9):1563-72
  • Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64(9):1553-62
  • Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-23
  • Lee M, Bard F, Johnson-Wood K, et al. Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies. Ann Neurol 2005;58(3):430-5
  • Levites Y, Smithson LA, Price RW, et al. Insights into the mechanisms of action of anti-Aβ antibodies in Alzheimer's disease mouse models. FASEB J 2006;20(14):2576-8
  • Masliah E, Hansen L, Adame A, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64(1):129-31
  • Morgan D. Mechanisms of Aβ plaque clearance following passive Aβ immunization. Neurodegener Dis 2005;2(5):261-6
  • Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9(4):448-52
  • Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61(1):46-54
  • Patton RL, Kalback WM, Esh CL, et al. Amyloid-β peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006;169(3):1048-63
  • Martin-Jones Z, Lasagna-Reeves C. Which is a better target for AD immunotherapy, Aβ or tau? Alzheimer Dis Assoc Disord 2008;22(2):111-2
  • Gotz J, Streffer JR, David D, et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 2004;9(7):664-83
  • Hardy J. Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 2006;3(1):71-3
  • Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007;4(4):473-8
  • Green RC, Schneider LS, Hendrix SB, et al. Safety and efficacy of Tarenflurbil in subjects with mild Alzheimer's disease: results from an 18-month multi-center Phase III trial. Alzheimers Dementia 2008;4(4 Suppl 2):T165
  • Chiang PK, Lam MA, Luo Y. The many faces of amyloid β in Alzheimer's disease. Curr Mol Med 2008;8(6):580-4
  • Gongadze N, Antelava N, Kezeli T, et al. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. Georgian Med News 2008;(155):44-8
  • Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 2008;4(2):65-79
  • Games D, Bard F, Grajeda H, et al. Prevention and reduction of AD-type pathology in PDAPP mice immunized with Aβ1–42. Ann NY Acad Sci 2000;920:274-84
  • Janus C, Pearson J, McLaurin J, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408(6815):979-82
  • Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400(6740):173-7
  • Bombois S, Maurage CA, Gompel M, et al. Absence of β-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol 2007;64(4):583-7
  • Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002;5(5):452-7
  • Asami-Odaka A, Obayashi-Adachi Y, Matsumoto Y, et al. Passive immunization of the Aβ42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener Dis 2005;2(1):36-43
  • Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6(8):916-9
  • DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98(15):8850-5
  • Gray AJ, Sakaguchi G, Shiratori C, et al. Antibody against C-terminal Aβ selectively elevates plasma Aβ. Neuroreport 2007;18(3):293-6
  • Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22(15):6331-5
  • Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003;23(34):10879-83
  • Mohajeri MH, Saini K, Schultz JG, et al. Passive immunization against β-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002;277(36):33012-7
  • Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1(1):24. Published online 8 December 2004 doi:10.1186/1742-2094-1-24
  • Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci 2005;8(1):79-84
  • Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem 2006;281(7):4292-9
  • Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;11(3):213-28
  • Bacher M, Depboylu C, Du Y, et al. Peripheral and central biodistribution of 111In-labelled anti-beta-amyloid anitbodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2007;449(3):240-5
  • Lee EB, Leng LZ, Lee VM, Trojanowski JQ. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett 2005;579(12):2564-8
  • Burbach GJ, Vlachos A, Ghebremedhin E, et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging 2007;28(2):202-12
  • Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. Expert Rev Vaccines 2004;3(6):717-25
  • Gandy S, Walker L. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-β vaccination in nonhuman primates. Curr Opin Immunol 2004;16(5):607-15
  • Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002;298(5597):1379
  • Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci 2005;25(3):629-36
  • Wilcock DM, Jantzen PT, Li Q, et al. Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 2007;144(3):950-60
  • Levites Y, Das P, Price RW, et al. Anti-Aβ42-and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006;116(1):193-201
  • Siemers E, Friederich S, Dean RA, et al. Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dementia 2008;4(4 suppl 2):T774
  • Grundman M, Black R. Clinical trials of Bapineuzumab, a beta-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers Dementia 2008;4(4 suppl 2):T166
  • Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75(10):1472-4
  • Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008; published online online 21 February 2008, doi:10.1016/j.neurobiolaging.2007.12.021
  • Tsakanikas D, Shah K, Flores C, et al. Effects of uninterrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months. Alzheimers Dementia 2008;4(4 suppl 2):T776
  • Tucker SM, Borchelt DR, Troncoso JC. Limited clearance of pre-existing amyloid plaques after intracerebral injection of Aβ antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol 2008;67(1):30-40
  • Rakover I, Arbel M, Solomon B. Immunotherapy against APP β-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain Aβ levels. Neurodegener Dis 2007;4(5):392-402
  • Liu R, Yuan B, Emadi S, et al. Single chain variable fragments against β-amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. Biochemistry 2004;43(22):6959-67
  • Poduslo JF, Ramakrishnan M, Holasek SS, et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007;102(2):420-33
  • Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol Aging 2004;25(5):599-602; discussion 603-4
  • Prada CM, Garcia-Alloza M, Betensky RA, et al. Antibody-mediated clearance of amyloid-β peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. J Neurosci 2007;27(8):1973-80
  • Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-β in PDAPP mice. J Neurosci 2008;28(27):6787-93
  • Belmouaz S, Desport E, Leroy F, et al. Posterior reversible encephalopathy induced by intravenous immunoglobulin. Nephrol Dial Transplant 2008;23(1):417-9
  • Koichihara R, Hamano S, Yamashita S, Tanaka M. Posterior reversible encephalopathy syndrome associated with IVIG in a patient with Guillain-Barre syndrome. Pediatr Neurol 2008;39(2):123-5
  • Mathy I, Gille M, Van Raemdonck F, et al. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature. Acta Neurol Belg 1998;98(4):347-51
  • Nakajima M. Posterior reversible encephalopathy complicating intravenous immunoglobulins in a patient with Miller–Fisher syndrome. Eur Neurol 2005;54(1):58-60
  • Van Diest D, Van Goethem JW, Vercruyssen A, et al. Posterior reversible encephalopathy and Guillain-Barre syndrome in a single patient: coincidence or causative relation? Clin Neurol Neurosurg 2007;109(1):58-62
  • Railey MD, Adair MA, Burks AW. Allergen immunotherapy for allergic rhinitis. Curr Allergy Asthma Rep 2008;8(1):1-3
  • Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J Nephrol 1998;11(3):157-61
  • Eibl MM. Intravenous immunoglobulins in neurological disorders: safety issues. Neurol Sci 2003;24(Suppl 4):S222-6
  • Gupta N, Ahmed I, Nissel-Horowitz S, et al. Intravenous gammglobulin-associated acute renal failure. Am J Hematol 2001;66(2):151-2
  • Haskin JA, Warner DJ, Blank DU. Acute renal failure after large doses of intravenous immune globulin. Ann Pharmacother 1999;33(7-8):800-3
  • Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004;83(10):661-5
  • Jolles S, Sewell WA, Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 2000;22(3):215-26
  • Nettis E, Calogiuri G, Colanardi MC, et al. Drug-induced aseptic meningitis. Curr Drug Targets Immune Endocr Metabol Disord 2003;3(2):143-9
  • Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney–a two-edged sword. Semin Arthritis Rheum 2004;34(3):593-601
  • Zaidan R, Al Moallem M, Wani BA, et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003;10(4):367-72
  • Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007;69(16):1622-34
  • Galasko D. Biomarkers for Alzheimer's disease–clinical needs and application. J Alzheimers Dis 2005;8(4):339-46
  • Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 2008;13(2):85-115
  • Solomon PR, Murphy CA. Early diagnosis and treatment of Alzheimer's disease. Expert Rev Neurother 2008;8(5):769-80
  • Sramek JJ, Veroff AE, Cutler NR. Mild cognitive impairment: emerging therapeutics. Ann Pharmacother 2000;34(10):1179-88
  • Bartus RT, Dean RL 3rd. Pharmaceutical treatment for cognitive deficits in Alzheimer's disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl) 2009;202(1-3):15-36
  • Oddo S, Billings L, Kesslak JP, et al. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43(3):321-32
  • Yang DS, Serpell LC, Yip CM, et al. Assembly of Alzheimer's amyloid-beta fibrils and approaches for therapeutic intervention. Amyloid 2001;8(Suppl 1):10-9
  • Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI. A 48-week randomized, placebo-controlled trial. Neurology 2009; published online 28 January 2009, doi:10.1212/01.wnl.0000344650.95823.03
  • Gauthier SG. Alzheimer's disease: the benefits of early treatment. Eur J Neurol 2005;12(Suppl 3):11-6
  • Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry 2006;77(4):429-38
  • Kirshner HS. Mild cognitive impairment: to treat or not to treat. Curr Neurol Neurosci Rep 2005;5(6):455-7
  • Levey A, Lah J, Goldstein F, et al. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther 2006;28(7):991-1001
  • Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007;4(11):e338. Published online November 27, 2007, doi:10.1371/journal.pmed.0040338

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.